Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jul 13, 2010


Harold Varmus has been sworn in as director of the National Cancer Institute of the National Institutes of Health. Most recently, he was the president of Memorial Sloan-Kettering Cancer Center in New York. Before that, from 1993 until 1999, he was the director of NIH, and prior to that, he spent 23 years as a faculty member at the University of California, San Francisco, medical school. In 1989, Varmus received the Nobel Prize in physiology or medicine for studies of the genetic basis of cancer.

Gerald Möller has joined the board of directors of Illumina, which has grown from eight to nine members. He is an advisor at HBM Bio Ventures, a Swiss investment firm. Previously, he spent 23 years at Boehringer Mannheim in Germany, Japan, and the US, where he held a number of positions, including CEO of the worldwide Boehringer Mannheim group. After Roche acquired the company, Möller became head of global development and strategic marketing, pharmaceuticals, and a member of Hoffmann LaRoche's executive committee. He is currently also a board member of Bionostics, Morphosys, and Vivacta as well as the chairman of the Foundation for Innovative New Diagnostics. Möller holds a PhD in physical chemistry from the University of Kiel in Germany.

Harold Swerdlow has joined the board of advisors of nanopore sequencing company NobleGen BioSciences. He is the head of sequencing technology at the Wellcome Trust Sanger Institute. Previously, he was chief technology officer at the Dolomite Centre, and senior director of research at Solexa (now Illumina). Swerdlow holds a PhD in bioengineering from the University of Utah and a BS in physics and mathematics from the University of California, Santa Cruz.

Gary King
has joined Myriad Genetics as executive vice president of international operations, a new position. He will oversee all aspects of the company's expansion into Europe and other international markets, including operations, sales and marketing, regulatory approval, and pricing and reimbursement. King comes to Myriad from AverDx, where he was CEO. Prior to that, he was vice president for international operations at Biosite, and before that, division director in Japan for Guidant. King holds an MBA from Stanford University and a BA in zoology from Pomona College.
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.